Literature DB >> 32087218

IRF-1 mediates the suppressive effects of mTOR inhibition on arterial endothelium.

Kai Peng1, Xing Fan1, Qiannan Li1, Yiying Wang1, Xiaolin Chen1, Pingxi Xiao2, Anthony G Passerini3, Scott I Simon3, ChongXiu Sun4.   

Abstract

AIMS: Mammalian target of rapamycin (mTOR) inhibitors used in drug-eluting stents (DES) to control restenosis have been found to delay endothelialization and increase incidence of late-stent thrombosis through mechanisms not completely understood. We revealed that mTOR inhibition (mTORi) upregulated the expression of cell growth suppressor IRF-1 in primary human arterial endothelial cells (HAEC). This study aimed to examine how mTOR-regulated IRF-1 expression contributes to the suppressive effect of mTORi on arterial endothelial proliferation. METHODS AND
RESULTS: Western blotting, quantitative PCR, and a dual-luciferase reporter assay indicated that mTOR inhibitors rapamycin and torin 1 upregulated IRF-1 expression and increased its transcriptional activity. IRF-1 in turn contributed to the suppressive effect of mTORi by mediating HAEC apoptosis and cell cycle arrest in part through upregulation of caspase 1 and downregulation of cyclin D3, as revealed by CCK-8 assay, Annexin V binding assay, measurement of activated caspase 3, BrdU incorporation assay, and matrigel tube formation assay. In a mouse model of femoral artery wire injury, administration of rapamycin inhibited EC recovery, an effect alleviated by EC deficiency of IRF-1. Chromatin immunoprecipitation assay with HAEC and rescue expression of wild type or dominant-negative IRF-1 in EC isolated from Irf1-/- mice confirmed transcriptional regulation of IRF-1 on the expression of CASP1 and CCND3. Furthermore, mTORi activated multiple PKC members, among which PKCζ was responsible for the growth-inhibitory effect on HAEC. Activated PKCζ increased IRF1 transcription through JAK/STAT-1 and NF-κB signaling. Finally, overexpression of wild type or mutant raptor incapable of binding mTOR indicated that mTOR-free raptor contributed to PKCζ activation in mTOR-inhibited HAEC.
CONCLUSIONS: The study reveals an IRF-1-mediated mechanism that contributes to the suppressive effects of mTORi on HAEC proliferation. Further study may facilitate the development of effective strategies to reduce the side effects of DES used in coronary interventions.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cell proliferation; Drug-eluting stents; Endothelium; Transcription factor; mTOR

Mesh:

Substances:

Year:  2020        PMID: 32087218      PMCID: PMC7138750          DOI: 10.1016/j.yjmcc.2020.02.006

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  53 in total

Review 1.  Cell signaling and function organized by PB1 domain interactions.

Authors:  Jorge Moscat; Maria T Diaz-Meco; Armando Albert; Sonsoles Campuzano
Journal:  Mol Cell       Date:  2006-09-01       Impact factor: 17.970

2.  One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis.

Authors:  Gaku Nakazawa; Marc Vorpahl; Aloke V Finn; Jagat Narula; Renu Virmani
Journal:  JACC Cardiovasc Imaging       Date:  2009-05

3.  Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents.

Authors:  Giovanni G Camici; Jan Steffel; Ilijana Amanovic; Alexander Breitenstein; Janette Baldinger; Stephan Keller; Thomas F Lüscher; Felix C Tanner
Journal:  Eur Heart J       Date:  2009-06-29       Impact factor: 29.983

4.  Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials.

Authors:  Anthony A Bavry; Dharam J Kumbhani; Thomas J Helton; Przemyslaw P Borek; Girish R Mood; Deepak L Bhatt
Journal:  Am J Med       Date:  2006-12       Impact factor: 4.965

5.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

Authors:  Dos D Sarbassov; Siraj M Ali; Shomit Sengupta; Joon-Ho Sheen; Peggy P Hsu; Alex F Bagley; Andrew L Markhard; David M Sabatini
Journal:  Mol Cell       Date:  2006-04-06       Impact factor: 17.970

6.  Molecular characterization of the gene for human interleukin-1 beta converting enzyme (IL1BC).

Authors:  D P Cerretti; L T Hollingsworth; C J Kozlosky; M B Valentine; D N Shapiro; S W Morris; N Nelson
Journal:  Genomics       Date:  1994-04       Impact factor: 5.736

7.  Rapamycin regulates endothelial cell migration through regulation of the cyclin-dependent kinase inhibitor p27Kip1.

Authors:  Stephanie C Moss; Daniel J Lightell; Steven O Marx; Andrew R Marks; T Cooper Woods
Journal:  J Biol Chem       Date:  2010-01-22       Impact factor: 5.157

8.  EGFR induces expression of IRF-1 via STAT1 and STAT3 activation leading to growth arrest of human cancer cells.

Authors:  Peter Andersen; Mikkel Wandahl Pedersen; Anders Woetmann; Mette Villingshøj; Marie-Thérése Stockhausen; Niels Odum; Hans Skovgaard Poulsen
Journal:  Int J Cancer       Date:  2008-01-15       Impact factor: 7.396

9.  Rapamycin antagonizes TNF induction of VCAM-1 on endothelial cells by inhibiting mTORC2.

Authors:  Chen Wang; Lingfeng Qin; Thomas D Manes; Nancy C Kirkiles-Smith; George Tellides; Jordan S Pober
Journal:  J Exp Med       Date:  2014-02-10       Impact factor: 14.307

10.  Interferon Regulatory Factor-1 Mediates Alveolar Macrophage Pyroptosis During LPS-Induced Acute Lung Injury in Mice.

Authors:  Dongdong Wu; Pinhua Pan; Xiaoli Su; Lemeng Zhang; Qingwu Qin; Hongyi Tan; Li Huang; Yuanyuan Li
Journal:  Shock       Date:  2016-09       Impact factor: 3.454

View more
  5 in total

1.  Cells or drugs? The race to regenerate the heart.

Authors:  Benjamin Plackett
Journal:  Nature       Date:  2021-06       Impact factor: 49.962

2.  The Fibrotic Effects of TMAO on Human Renal Fibroblasts Is Mediated by NLRP3, Caspase-1 and the PERK/Akt/mTOR Pathway.

Authors:  Stefania Kapetanaki; Ashok Kumar Kumawat; Katarina Persson; Isak Demirel
Journal:  Int J Mol Sci       Date:  2021-11-01       Impact factor: 5.923

3.  mTOR contributes to endothelium-dependent vasorelaxation by promoting eNOS expression and preventing eNOS uncoupling.

Authors:  Yiying Wang; Qiannan Li; Zhiyang Zhang; Kai Peng; Dai-Min Zhang; Qianlu Yang; Anthony G Passerini; Scott I Simon; ChongXiu Sun
Journal:  Commun Biol       Date:  2022-07-22

4.  The role of Th9 CD4+ T cells and IL-9 during primary Sjogren's syndrome.

Authors:  Jie Yang; Juan Su; Kexia Chai; Huihui Liu
Journal:  J Clin Lab Anal       Date:  2022-08-09       Impact factor: 3.124

Review 5.  Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours.

Authors:  Fei Xu; Lixin Na; Yanfei Li; Linjun Chen
Journal:  Cell Biosci       Date:  2020-04-01       Impact factor: 7.133

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.